Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
Open Access
- 10 November 2009
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 101 (11), 1833-1838
- https://doi.org/10.1038/sj.bjc.6605422
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)European Urology, 2009
- Stage-specific survival of epithelial cancers in North-Holland/Flevoland, The NetherlandsEuropean Journal of Cancer, 2005
- COMPARISON OF SCREEN DETECTED AND CLINICALLY DIAGNOSED PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAMJournal of Urology, 2005
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI Journal of the National Cancer Institute, 2003
- Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate CancerInternational Journal of Cancer, 2003
- Comparing the Costs of Radiation Therapy and Radical Prostatectomy for the Initial Treatment of Early-Stage Prostate CancerJournal of Clinical Oncology, 2002
- Advanced prostate cancer: Course, care, and cost implicationsThe Prostate, 1999
- Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot StudyAnnals of Oncology, 1998
- Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapyUrology, 1997
- Cost benefit of emerging technology in localized carcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1997